ArticleBMC cancer2014

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Noriyuki Koyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.